About US
Contact us
-
Novartis Moves for Potent Hepatitis C TreatmentNovartis has moved to seal an exclusive licence agreement with Swiss group Debiopharm for the development, manufacture and commercialisation of Debio 025 (alisporivir), which has shown a potent effe2010/2/11
-
New brilliance in coatings design: Paliocrom®Brilliant Orange from BASFNew generation of effect pigments Ultra-high chroma and excellent hiding power Paliocrom® Brilliant Orange L 2850 is the first of a new generation of effect pigments from BASF. Exceptional2010/2/10
-
Frost & Sullivan's report on rheumatoid arthritis therapeutics market in ThailandResearch and Markets (http://www.researchandmarkets.com/research/1c756d/rheumatoid_arthrit) has announced the addition of Frost & Sullivan's new report "Rheumatoid Arthritis Therapeutics Market in2010/2/10
-
Survey reveals need for better access to levalbuterol for asthma patientsA recent electronic survey of US asthma experts demonstrated the need for better access to levalbuterol, the fast-acting medicine used to treat the narrowing of airways (bronchospasm) caused by asthma2010/2/10
-
Actavis To Expand Iceland FacilityActavis has said that it will be expanding its manufacturing site in Iceland, whereby increasing capacity at the site by 50%. With this decision, the company also intends to create 50 new jobs. The c2010/2/9
-
GSK Forms New Specialized R&D UnitGSK has established a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. Marc Dunoyer, president of Asia Pacific and chairman of Japan at GSK, is2010/2/9
-
BASF Venture Capital invests in Canadiancompany Quantiam Technologies Inc.Investment of €2 million with the main focus on catalytically active coatings for steam cracker furnace tubes Ludwigshafen , Germany – February 4, 2010 – BASF Venture Capital GmbH, Ludwigshafen, i2010/2/9
-
Avexa Announces Positive HIV Therapy TrialsAustralia's Avexa has announced positive results from a Phase III study of apricitabine (ATC), a new therapy to treat patients with HIV. The Phase III trial compared ATC to 3TC in drug-resistant HI2010/2/8
-
Shire Applies For Fabry Drug Licensing in USShire has submitted a Biologics License Application to the US Food and Drug Administration (FDA) for Replagal, an enzyme replacement therapy for Fabry disease. Replagal first received marketing aut2010/2/8
-
BASF and Embrapa’s Cultivance®soybeans receive approval for commercial cultivation in BrazilFirst genetically modified crop developed in Brazil to reach commercialization stage Market launch to take place after regulatory approval in key export markets Brasília and São Paulo Braz2010/2/8